Gonadorelin

A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). When administered in a pulsatile fashion, it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, supporting natural testosterone and estrogen production.

• Binds GnRH receptors (GnRHR) on anterior pituitary gonadotrophs to stimulate LH and FSH secretion
• Pulsatile administration mimics endogenous GnRH pulse generator, maintaining receptor sensitivity
• Continuous administration (non-pulsatile) causes receptor downregulation and gonadotropin suppression

• Hormone-dependent malignancies
• Pregnancy or breastfeeding
• Known hypersensitivity to GnRH or analogs

Store at 2–8°C (36–46°F) for up to 6 months. Once reconstituted, refrigerate and use within 14 days. Some formulations may be stored at room temperature prior to reconstitution.

Gonadorelin was FDA-approved under the brand names Factrel (for diagnostic use) and Lutrepulse (for pulsatile therapeutic use in hypothalamic amenorrhea). It is the gold-standard diagnostic agent for assessing pituitary GnRH responsiveness. In research and clinical practice, pulsatile gonadorelin has been used to restore fertility in patients with hypothalamic hypogonadism. It has gained renewed interest in the peptide community for maintaining endogenous hormone production alongside testosterone replacement therapy.